News Hub | News Direct

Healthcare

Addiction Biotech Cannabis Genetics Healthcare Medical Devices Pharmaceutical Science Veterinary
Article thumbnail News Release

BiVictriX Therapeutics appoints combined CFO/CBO to boost out-licensing efforts

BiVictriX Therapeutics PLC

BiVictriX Therapeutics PLC (AIM:BVX, OTC:BVTXF) incoming chief financial officer Adrian Howd speaks to Thomas Warner from Proactive London about what he hopes to achieve in the new role, which is being combined with the newly-created position of chief business officer. Howd introduces himself, highlighting his 20+ years in the biotech sector and the roles he's played in several emerging biotech companies and investment ventures. At BiVictriX, he will lead negotiations with larger companies interested in their evolving products. Howd expresses his confidence in the potential of BiVictriX's product pipeline and its lead asset BVX001 in particular, saying that its "a molecule that looks really different to other products... the antibody drug conjugate space is fairly new... but its the fastest growing element of new cancer therapy." Despite challenges in the broader biotech sector, Howd expressed confidence in BiVictriX's future, praising its scientific approach and the achievement of the team so far. Contact Details Proactive UK Ltd +44 20 7989 0813 uk@proactiveinvestors.com

October 06, 2023 03:00 AM Eastern Daylight Time

Video
Article thumbnail News Release

Safe Supply Streaming Co now trading on the Canadian Securities Exchange with ticker SPLY

Safe Supply Streaming Co Ltd

Safe Supply Streaming Co CEO Bill Panagiotakopoulos and advisor Ronan Levy joined Steve Darling from Proactive to share news that the company has commenced trading on the Canadian Securities Exchange under the ticker symbol 'SPLY.' The company, with its strong financial footing, is strategically aligned with pivotal drug policy reform movements around the world. Panagiotakopoulos explained that Safe Supply Streaming is a pioneering company that invests in the legal and regulated supply of drugs that were traditionally only accessible through illicit markets. The company is actively deploying capital to address the ongoing fentanyl crisis and emerging opportunities related to the coca plant. Levy says the company's focus is on investing in and incubating businesses throughout the safe supply value chain. This includes companies that offer products, solutions, and technologies to combat the physical, financial, and emotional damage caused by drug abuse. Safe Supply Streaming Co's commitment to drug policy reform and harm reduction positions it at the forefront of a critical global issue. Contact Details Proactive Investors +1 604-688-8158 na-editorial@proactiveinvestors.com

October 05, 2023 01:30 PM Eastern Daylight Time

Video
Article thumbnail News Release

1606 announces launch of revolutionary AI chatbot to enhance customer experiences is expected soon

1606 Corp.

1606 Corp CEO Greg Lambrecht joined Steve Darling from Proactive to share news that the company’s new AI chatbot ChatCBD, which is designed to revolutionize the customer experience will soon be live. Lambrecht explained that ChatCBD, developed in partnership with Cool Blue Distribution, is a comprehensive and custom-tailored tool that aims to respond to customer inquiries related to CBD and provide product recommendations from a range of retail brands available through Cool Blue Distribution, a prominent CBD distributor in the United States. What sets ChatCBD apart is its incorporation of Natural Language Processing technology, which enables it to respond to customer queries with a remarkable degree of precision and understanding, akin to human interactions. The chatbot operates 24/7, ensuring that customers receive prompt assistance and solutions to their questions, even outside regular business hours. This innovative approach not only enhances the customer experience but also showcases 1606 Corp's commitment to leveraging cutting-edge technology to provide valuable solutions in the growing CBD market. By offering an AI-driven chatbot for CBD-related inquiries and product recommendations, 1606 Corp aims to create a seamless and informative shopping experience for consumers exploring the world of CBD products. This initiative underscores the company's dedication to staying at the forefront of the CBD industry. Contact Details Proactive Canada +1 604-688-8158 na-editorial@proactiveinvestors.com

October 05, 2023 12:10 PM Eastern Daylight Time

Video
Article thumbnail News Release

Addex Therapeutics focused on securing new partnerships to fund promising treatments

Addex Therapeutics Ltd

Addex Therapeutics co-founder and CEO Tim Dyer speaks to Thomas Warner from Proactive about the work that the central nervous system-focused clinical-stage pharmaceutical company has been doing in the promising area of allosteric modulation. He explains that company is currently collaborating with Johnson & Johnson on a phase two study for epilepsy, with results expected in Q2 of the following year. Additionally, Addex is developing treatments for chronic cough, schizophrenia, and cognition, with the latter receiving a grant from the European Union. Dyer explains that the company's unique approach to allosteric modulation offers a competitive edge in drug discovery, setting them apart from competitors. Their long-term strategy revolves around advancing their programs and securing partnerships to ensure steady cash inflows, especially given the challenging capital market environment. With seven programs in the pipeline and two already partnered, Addex is poised for significant growth in the coming years. Dyer says that "at the moment we continue to move the programs forward... we're very focused today on securing cash inflows to keep the business going through partnerships." Contact Details Proactive United States Proactive United States +1 347-449-0879 action@proactiveinvestors.com

October 05, 2023 11:20 AM Eastern Daylight Time

Video
Article thumbnail News Release

Shield Therapeutics' pricing will be "key metric" - Proactive Research Analyst

Shield Therapeutics PLC

Proactive Research Analyst Robin Davison speaks to Thomas Warner after publishing a new research note on iron defiency-focused commercial-stage specialty pharmaceutical company Shield Therapeutics. Davison gives an overview of what readers can expect from the note, highlighting Shield's recent half-year results and accompanying financing transactions. The company's burgeoning relationship with commercial partner Viatris is a key focus. While the product's trajectory is promising, Davison explains that Shield has been grappling with the challenge of drug reimbursements in the US, leading to the incurring of some costs. However, plans are underway to assist doctors in navigating this system, with a view to securing a higher average drug price. Davison suggests that Shield's ability to increase that average price will be a "key metric going forward." He concludes by saying that "the trajectory is going extremely well, [they' really just want to get the pricing issue sorted now and it should be a great story." Davison's research note is available on the Proactive website as is a interview with Shield Therapeutics' CEO Greg Madison. Contact Details Proactive UK Ltd +44 20 7989 0813 uk@proactiveinvestors.com

October 05, 2023 04:00 AM Eastern Daylight Time

Video
Article thumbnail News Release

Northern Leaf "on the road in terms of sales" ahead of London listing

Northern Leaf

Northern Leaf CEO Don Perrott speaks to Thomas Warner from Proactive London about the Jersey-based medical cannabis company's progress towards a potential AIM-listing later this year. Perrott gives an overview of the business and its achievements since being incorporated in 2019, highlighting its 100,000 square-foot glasshouse facility that produces six to eight tonnes of medical cannabis annually and its its EU Good Manufacturing Practice (GMP) and Good Clinical Practice (GCP certifications). He discusses the benefits the advantages of operating in Jersey, which include a supportive government and competitive electricity costs. Northern Leaf is gearing up for a listing on AIM in the fourth quarter, with substantial progress already made in its IPO preparations. Perrott emphasises the commitment to producing high-quality, consistent medical cannabis and says the company is "on the road in terms of sales" with a shipment already on its way to Australia and deliveries to the UK and Germany scheduled. Perrott also expresses confidence in Northern Leaf's ability to navigate an often complex regulatory environment, saying that the company is "on top of regulations" and embracing the opportunities being created. Contact Details Proactive UK Ltd Proactive UK Ltd +44 20 7989 0813 uk@proactiveinvestors.com

October 05, 2023 03:57 AM Eastern Daylight Time

Video
Article thumbnail News Release

Shield Therapeutics "couldn't be more pleased" with Viatris collaboration

Shield Therapeutics PLC

Shield Therapeutics PLC (AIM:STX, OTCQX:SHIEF) CEO Greg Madison speaks to Thomas Warner after a busy week for the commercial stage pharmaceutical company, which included the release of its interim results and the announcement of a major fundraise. He highlights the success of the fundraise, which comprised US$20 million from a new senior debt facility as well as an equity fundraise (split between a share placing, a subscription and an offering to retail investors) that brought in an additional US$6 million. He explains that the new funding is going to be put to use in "paying off an existing loan, increasing our working capital needs and then certainly some commercial investments to accelerate the curve that we're seeing here." The curve he describes is the marked increase in demand for Shield's Accrufer product, which is a stable, non-salt based oral therapy for adults with iron deficiency that is designed to avoid some of the unwanted side-effects of conventional iron tablets. He says he "can't speak highly enough about the dedication and passion of [his] team at Shield, but also about our partner Viatris... we made an excellent choice... we couldn't be more pleased with the partnership and the collaboration we're seeing." Contact Details Proactive UK Ltd +44 20 7989 0813 uk@proactiveinvestors.com

October 05, 2023 03:00 AM Eastern Daylight Time

Video
Article thumbnail News Release

Nuformix to fund its unlicensed programs with NXP001 windfall

Nuformix PLC

Nuformix PLC (LSE:NFX) executive director Dr Dan Gooding speaks to Proactive after the pharmaceutical development company announced it is to receive new immediate and near-term milestone payments as part of an update to its NXP001 exclusive licensing agreement with Oxilio Ltd. Dr. Gooding explains that Oxilio has now purchased patents from Nuformix that it had previously been licencing, resulting in significant near-term payments to Nuformix. This financial boost will aid Nuformix in advancing their unlicensed programs, specifically NXP002 and NXP004. Despite the patent sale, Nuformix retains future value from NXP001 through development milestones and royalties. Dr. Gooding also highlights Nuformix's work with NXP002 on lung fibrosis, a severe disease with limited treatment options. He explains that Nuformix's approach of repurposing existing drugs means a reduction in research time and costs. NXP002 is a modified version of a drug initially approved in Japan for asthma and skin scarring treatment. Contact Details Proactive UK Ltd +44 20 7989 0813 uk@proactiveinvestors.com

October 05, 2023 03:00 AM Eastern Daylight Time

Video
Article thumbnail News Release

NMTC Coalition, 700 Organizations Urge White House, Congressional Leadership to Make NMTC Program Permanent

New Markets Tax Credit Coalition

Today, the New Markets Tax Credit (NMTC) Coalition, a national membership organization of Community Development Entities (CDEs) and investors organized to advocate on behalf of the NMTC, released a letter signed by nearly 700 community development stakeholders to President Biden and Members of Congress in support of enactment of a permanent extension to the NMTC in end of the year tax legislation. Despite its efficacy and importance for businesses and community development projects, the NMTC program expires in 2025. Signatories on the letter include 275 community development organizations; 76 housing organizations; 140 nonprofits, shelters, schools, healthcare facilities, and community service providers; 166 businesses and community development-focused investors; and 31 state and national community development trade associations. “We strongly support making the NMTC permanent,” said Aisha Benson, President of the NMTC Coalition and President and CEO of Nonprofit Finance Fund. “We’ve seen the enormous impact NMTCs can have in strengthening communities across the country, as well as in our own work in Arkansas and Ohio. We are committed to ensuring no community is left behind and preserving one of the federal government’s most successful community development programs.” During this Congress, both the Senate and House introduced bills (S. 234 and H.R. 2539) with bipartisan support to make the NMTC extension permanent. Establishing permanence will provide certainty in delivering resources to low-income and marginalized communities, creating jobs, increasing economic opportunity, and improving lives at a time when underserved communities face significant challenges. Throughout its 20-year history, the NMTC has delivered more than $125 billion to rural and urban communities outside the economic mainstream, which has led to financing to more than 8,000 businesses and projects and over one million jobs. Establishing the NMTC as a permanent part of the tax code will provide certainty and further promote getting patient, flexible capital to low-income and marginalized communities, creating jobs, increasing economic opportunity, and improving lives at a time when the economic frailty of our underserved communities has never been more apparent. Established in 2000 in the Community Renewal Tax Relief Act (P.L.106-554), the New Markets Tax Credit is a bipartisan effort to stimulate investment and economic growth in low-income urban neighborhoods and rural communities. “With the continuing impacts from COVID-19, and the general economic uncertainty felt across the country, the New Markets Tax Credit is absolutely vital for many of America’s urban neighborhoods and rural communities and will provide billions of dollars for high-impact, community revitalization projects,” said Bob Rapoza, spokesperson for the NMTC Coalition. “Over the years, the credit has been instrumental in financing plant and equipment for small manufacturing businesses and patient, flexible capital to other small businesses, hospitals, healthcare centers, homeless shelters and other transformative projects that improve communities, create jobs and economic opportunity. A permanent extension of NMTC will provide more certainty to private sector investors, which will result in better pricing and more subsidy to hard-to-finance, essential projects.” For examples of how the NMTC is making an impact in each state, see the NMTC Coalition’s website, where you can find over 2,500 NMTC success stories organized by state and congressional district. About New Markets Tax Credit Program -- The New Markets Tax Credit (NMTC) was enacted in 2000 to stimulate private investment and economic growth in low-income urban neighborhoods and rural communities lacking the patient capital to support and grow businesses, create jobs, and sustain healthy local economies. Since its inception, the NMTC has generated more than one million jobs. Today due to NMTC, more than $120 billion is hard at work in underserved communities in all 50 states, the District of Columbia, Guam and Puerto Rico. For examples of how the NMTC impacts each state, see the NMTC Coalition’s project database and state fact sheets. For more information, visit www.NMTCCoalition.org. Contact Details Greg Wilson +1 571-239-7474 gregwilsonpr@gmail.com Company Website https://nmtccoalition.org/

October 04, 2023 12:27 PM Eastern Daylight Time

1 ... 8990919293 ... 310